Incyte | INCY - Debt


Incyte reported $38.27M in Debt for its fiscal quarter ending in June of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
Agenus USD 35.54M 2.34M Mar/2025
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Amgen USD 57.32B 2.72B Mar/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 8.09B 1.53B Jun/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
Exelixis USD 165.93M 3.61M Jun/2026
Gilead Sciences USD 22.17B 2.76B Mar/2026
Incyte USD 38.27M 1.16M Jun/2026
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
MacroGenics USD 36.51M 500K Mar/2026
Merck USD 49.12B 222M Mar/2026
Moderna USD 1.3B 7M Mar/2026
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 49.01B 2.02B Jun/2026
Novartis USD 47B 14.98B Mar/2026
Pfizer USD 63.19B 536M Jun/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.98B 8.9M Jun/2026